Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  denileukin diftitox
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 28 for your search:
Start Over
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: #33, NCT00211198
Phase III Randomized, Double-Blind Study of Two Doses of the IL-2 Receptor-Targeted Cytotoxin DAB389-IL2 for Recurrent or Persistent Cutaneous T-Cell Lymphoma (Summary Last Modified 02/96)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: SERAGEN-93-04-10, NCI-V95-0738
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7777-G000-302, NCT01871727
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: over 18
Sponsor: Other
Protocol IDs: CDR0000270762, ERLANGEN-ONTAK, EU-20246, NCT00056134
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6308, NCI-2010-00800, 127, UWCC-6308, UWCC-05-6951-A, NCT00425672
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: L4389-34, NCT00055146
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: CDR0000361715, NCI-04-C-0134, NCT00082914
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: #35, NCT00211185
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: #123, NCT00211276
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 050185, 05-C-0185, NCT00117845
Phase II Trial of Ontak With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 076.06, NCT00299689
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 0507000369, NCT00337987
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000539551, NCCTG-N0682, N0682, NCT00460109
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 10 and over
Sponsor: NCI, NHLBI
Protocol IDs: BMTCTN0302, U01HL069294-05, 285, JHOC-05040403, JHOC-J0519, NCT00224874
Vaccination Plus Ontak in Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 15232B, NCT00515528
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: UC-PTCL-ONTAK, NCT00632827
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066692, E1497, NCT00003615
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7272-701, NCT01127451
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000437795, DUMC-NCI-7042, NCI-7042, 7042, NCT00128622
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6193, NCI-2010-00832, UWCC-6193, UWCC-03-9836-D01, FHCRC-6193, FHCRC-UW-6193, FHCRC-119, NCT00357448
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6223, NCI-2009-01547, FHCRC-6223, UWCC-UW 6223, UWCC- 03-7469-D 01, UWCC-UW03011, FHCRC-6223p, NCT00228358
Start Over